These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29604484)

  • 1. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
    Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
    Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
    Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
    Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.
    Krauss G; Biton V; Harvey JH; Elger C; Trinka E; Soares da Silva P; Gama H; Cheng H; Grinnell T; Blum D
    Epilepsy Res; 2018 Jan; 139():1-8. PubMed ID: 29127848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
    Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
    Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures.
    Altalib H; Grinnell T; Cantu D; Ikedo F; Vieira M; Zhang Y; Blum D
    Epilepsia Open; 2022 Dec; 7(4):616-632. PubMed ID: 35908275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
    Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
    Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures.
    Mintz M; Pina-Garza JE; Wolf SM; McGoldrick PE; Józwiak S; Grinnell T; Cantu D; Costa R; Moreira J; Li Y; Blum D
    J Child Neurol; 2020 Mar; 35(4):265-273. PubMed ID: 31878820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
    Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
    Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
    Andermann E; Rosenfeld W; Penovich P; Rogin J; Cendes F; Carreño M; Ramsay RE; Ben-Menachem E; Gama H; Rocha F; Soares-da-Silva P; Tosiello R; Blum D; Grinnell T
    Epilepsy Res; 2021 Jan; 169():106478. PubMed ID: 33338829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
    Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
    Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
    Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
    CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.
    Mintzer S; Wechsler RT; Rogin JB; Gidal BE; Schwab M; Ben-Menachem E; Carreño M; da Silva PS; Moreira J; Li Y; Blum D; Grinnell T
    Epilepsy Res; 2018 Mar; 141():83-89. PubMed ID: 29499473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate.
    Rogin J; Resnick T; Strom L; Ben-Menachem E; Kochen S; Blum D; Gama H; Soares-da-Silva P; Li Y; Grinnell T
    Acta Neurol Scand; 2020 May; 141(5):397-404. PubMed ID: 31894578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial.
    Lee SK; Lee SA; Hong SB; Cho YW; Castilla-Fernández G; Fonseca MM; Moreira J; Gama H; Holenz J
    Clin Transl Sci; 2024 May; 17(5):e13802. PubMed ID: 38787305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
    Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
    Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.
    Gama H; Vieira M; Costa R; Graça J; Magalhães LM; Soares-da-Silva P
    Drug Saf; 2017 Dec; 40(12):1231-1240. PubMed ID: 28752473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures.
    Sankar R; Kirkham FJ; Holmes GL; Pina-Garza JE; Wheless J; Gama H; Moreira J; Cantu D; Tosiello R; Blum D; Grinnell T
    Epilepsy Behav; 2020 Nov; 112():107458. PubMed ID: 33181890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.
    Jóźwiak S; Veggiotti P; Moreira J; Gama H; Rocha F; Soares-da-Silva P
    Epilepsy Behav; 2018 Apr; 81():1-11. PubMed ID: 29454255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy.
    Wechsler RT; Radtke RA; Smith M; Vossler DG; Strom L; Trinka E; Cheng H; Grinnell T; Blum D; Vieira M; Moreira J; Rocha F
    Epilepsia; 2019 Jul; 60(7):1341-1352. PubMed ID: 31260089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
    Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
    Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.